证券日报网讯 12月11日晚间，重药控股发布公告称，公司股票于2025年12月10日、12月11日连续两个 交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。公司核实后表示，前期披露信息无 需更正补充，未发现未公开重大信息，经营情况正常，控股股东及实际控制人不存在应披露未披露重大 事项，亦未在异常波动期间买卖公司股票。 （文章来源：证券日报） ...

数据宝统计，截至10:59，重药控股成交额11.73亿元，创上市以来新高。最新股价下跌3.57%，换手率 10.55%。上一交易日该股全天成交额为2.02亿元。 据天眼查APP显示，重药控股股份有限公司成立于1999年05月28日，注册资本172818.4696万人民币。 （数据宝） （文章来源：证券时报网） ...

（文章来源：证券时报网） 据天眼查APP显示，重药控股股份有限公司成立于1999年05月28日，注册资本172818.4696万人民币。 （数据宝） 数据宝统计，截至10:12，重药控股成交额10.17亿元，创2023年5月11日以来新高。最新股价下跌 3.72%，换手率9.08%。上一交易日该股全天成交额为2.02亿元。 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-089 重药控股股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 二、公司关注、核实情况说明 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 3、近期公司经营情况正常，内外部经营环境不存在发生或预计将要发生重 大变化的情形。 4、经公司控股股东重庆医药健康产业有限公司复函确认，公司控股股东及 实际控制人不存在有关公司的应披露而未披露的重大事项、或者正处于筹划中的 重大事项。 5、股票交易异常波动期间，公司控股股东及实际控制人不存在买卖公司股 票的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，除公司已披露的信息外，本公司目前没有任何根据《深 圳证券交易所股票上市规则》等有关规定应予以披露而未披露的事项或与该事项 有关的筹划、商谈、意向、协议等；董事会也未获悉本公司存在《深圳证券交易 所股票上市规则》规定的应予以披露而未披露 ...

格隆汇12月11日｜重药控股晚间公告，公司股票于2025年12月10日、12月11日连续两个交易日收盘价格 涨幅偏离值累计超过20%，属于股票交易异常波动情况。经核实，公司前期披露的信息不存在需要更 正、补充之处，近期公司经营情况正常，内外部经营环境未发生重大变化。公司控股股东及实际控制人 不存在有关公司的应披露而未披露的重大事项或正处于筹划中的重大事项。股票交易异常波动期间，公 司控股股东及实际控制人不存在买卖公司股票的情形。 ...

证券日报网讯 12月10日晚间，重药控股发布公告称，2025年12月9日，参股子公司药友制药与上海复星 医药产业发展有限公司及辉瑞共同签订《Collaboration and License Agreement》，主要就口服小分子胰 高血糖素样肽（GLP-1R）激动剂（含YP05002）及含有该活性成分的产品授予辉瑞全球独家开发、生 产及商业化权利，药友制药将获不可退还首付款15000万美元及至多35000万美元开发里程碑付款。 （编辑 丛可心） ...

（编辑 丛可心） 证券日报网讯 12月10日晚间，重药控股发布公告称，控股子公司重药股份以公开挂牌方式转让持有的 化医财务公司20%股权，摘牌方即受让方为重庆建峰工业集团有限公司，转让价格26，477.11万元，化 医财务公司已于2025年12月9日完成工商变更登记，重药股份不再持有化医财务公司股权。 ...

截至收盘，上证指数报收3873.32点，下跌0.70%；深证成指收于13147.39点，下跌1.27%；创业板指下 跌1.41%；科创50指数下跌1.55%。 两市涨停股一览 证券时报·数据宝统计显示，涨停个股中，主板有32只，北交所2只，创业板2只，科创板2只。以所属行 业来看，上榜个股居前的行业有电力设备、机械设备、建筑材料行业，上榜个股分别有5只、4只、3 只。 涨停股中，*ST景峰、*ST铖昌等4只股为ST股。连续涨停天数看，东百集团已连收5个涨停板，连续涨 停板数量最多。从收盘涨停板封单量来看，重药控股最受资金追捧，收盘涨停板封单有5037.78万股， 其次是XR*ST宁、中超控股等，涨停板封单分别有4807.39万股、3562.40万股。以封单金额计算，南都 物业、重药控股、雪人集团等涨停板封单资金较多，分别有4.07亿元、3.25亿元、2.83亿元。（数据 宝） 不含当日上市新股，今日可交易A股中，上涨个股有1033只，占比18.98%，下跌个股有4378只，平盘个 股31只。其中，收盘股价涨停的有38只，跌停股有30只。 | 代码 | 简称 | 收盘价（元） | 换手率（%） | 涨停板封单（ ...

Market Overview - The Shanghai Composite Index fell by 0.70%, dropping below 3900 points, while the ChiNext and Shenzhen Composite Indexes both declined by over 1% [1] - More than 4300 stocks in the two markets experienced declines, with notable increases in stocks like Moer Thread, which surged nearly 30% [1] Aerospace and Defense - Aerospace Power has seen three consecutive trading days of gains, indicating strong market interest [3] - The company is a subsidiary of the China Aerospace Science and Technology Corporation, primarily engaged in the development of liquid rocket engines [3] Telecommunications and Technology - DreamNet Technology launched a rich media communication service for 5G, integrating various communication methods [5] - The company collaborates with Alibaba for cloud computing, enhancing its capabilities in key industries such as finance and public utilities [5] Energy and Utilities - Companies in the cable sector, such as Tongguang Cable, have seen significant stock price increases due to their involvement in national grid projects [3] - The company produces OPGW cables used in high-voltage power projects, integrating AI for improved fault location accuracy [3] Consumer Goods - Dongbai Group has maintained a strong market presence with six consecutive trading days of gains, focusing on retail and commercial real estate [5][7] - The company primarily operates in the department store sector while also engaging in property development and leasing [7] Renewable Energy - China Tianying is a leader in the domestic waste incineration power generation sector, with advancements in energy storage technology [7] - The company is expanding its operations into distributed photovoltaic power generation and wind energy [7] Robotics - Jiafeng Co. is involved in the precision reduction gear manufacturing for industrial robots, indicating growth in the robotics sector [7] - The company aims to provide standardized products and custom solutions for robot manufacturers [7] Real Estate - Vanke is reportedly discussing bond extension matters, indicating ongoing financial restructuring efforts [8] - The company is facing challenges but is actively seeking solutions to stabilize its financial position [8]

Core Viewpoint - Chongqing Yaoyou Pharmaceutical Co., Ltd. has signed a licensing agreement with Pfizer and Shanghai Fosun Pharmaceutical, granting Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 globally across all therapeutic areas for humans and animals [1][2]. Group 1: Financial Aspects - Yaoyou Pharmaceutical could receive up to $2.085 billion (approximately 15 billion RMB) from this agreement [2]. - Pfizer will pay an upfront non-refundable fee of up to $500 million, which includes an initial payment of $150 million and up to $350 million in milestone payments based on clinical trial and commercialization progress [2]. - Additionally, Pfizer will pay up to $1.585 billion in sales milestone payments based on the annual net sales of the licensed product, along with royalties calculated as a percentage of annual net sales [2]. Group 2: Product and Market Potential - YP05002 is an innovative GLP-1 receptor agonist developed by Yaoyou Pharmaceutical, aimed at treating type 2 diabetes, obesity, and related diseases by enhancing insulin secretion and reducing appetite [2][3]. - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and non-alcoholic fatty liver disease [3]. - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [3]. Group 3: Strategic Implications - The licensing agreement reflects recognition of Yaoyou Pharmaceutical's innovative research and development capabilities [3]. - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally, potentially benefiting more patients worldwide [3].